Get the Daily Brief
Latest Biotech News
Tempus AI Boosts Convertible Note Offering to $650 Million
Tempus AI increased its convertible senior notes offering from $400 million to $650 million to manage debt and reduce interest expenses. The Chicago-based precision medicine company offered notes...
Imagene AI Raises $23 Million Series B for Digital Pathology Models
Imagene AI, a Miami-based firm developing AI-enabled digital pathology tools, secured $23 million in a Series B financing round led by Oracle's Larry Ellison. The company uses advanced foundation...
Moderna’s mRNA Flu Vaccine Outperforms Competitors in Phase 3 Trial
Moderna announced top-line results from its Phase 3 trial of the mRNA-1010 seasonal influenza vaccine, showing a 26.6% relative vaccine efficacy compared to a licensed standard-dose shot in adults...
AbbVie Acquires Capstan Therapeutics to Expand In Vivo CAR-T Portfolio
AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, gaining access to Capstan’s in vivo CAR-T platform and its phase 1 autoimmune program targeting CD19. Capstan’s...
Novel Insights into Chemotherapy-Induced Genetic Damage Uncovered
Cutting-edge genomic studies from the Wellcome Sanger Institute, University of Cambridge, and Cambridge University Hospitals reveal distinct mutational signatures caused by various chemotherapy...
Breaking Ground in Psychedelic Therapy for Treatment-Resistant Depression
Beckley Psytech and Atai Life Sciences have reported promising results from mid-stage clinical trials of psychedelic-based treatments targeting treatment-resistant depression. Beckley's intranasal...
AI and Genomics Drive Breakthroughs Across Biotech Sector
The biotech sector is seeing rapid innovation at the intersection of artificial intelligence (AI) and genomics. Advances include AI-powered molecular diagnostics, computational drug discovery, and...
Psychedelic Therapy Advances in Treatment-Resistant Depression
Beckley Psytech has reported positive Phase 2b clinical trial results for its intranasal psychedelic compound BPL-003 in patients with treatment-resistant depression. The trial demonstrated...
AbbVie Expands In Vivo CAR-T Portfolio with Capstan Acquisition
AbbVie announced a $2.1 billion acquisition of Capstan Therapeutics, gaining rights to a phase 1-stage in vivo CAR-T therapy targeting CD19 and Capstan’s proprietary targeted lipid nanoparticle...
Moderna’s mRNA Flu Vaccine Achieves Phase 3 Superiority
Moderna reported positive Phase 3 data for its seasonal influenza vaccine mRNA-1010, demonstrating a 26.6% relative efficacy over a standard-dose comparator in adults 50 years and older across...
Genetic and Molecular Insights into Cancer and Neurological Disorders
Recent studies have uncovered key mechanisms impacting various cancers and neurodegenerative diseases. Groundbreaking research highlights the role of mutant p53 and SH3BGRL in cancer cell...
Advances in AI and Diagnostics in Healthcare
Innovations in artificial intelligence are reshaping diagnostics and therapy. A new AI-driven system from Kindai University enhances classification of facial pigmented lesions, while University of...
Continued Challenges and Setbacks in Drug Development Pipelines
Pharma companies face notable hurdles as INmune Bio’s Alzheimer’s disease program missed key Phase 2 endpoints despite subgroup benefits, and Pfizer terminated one of two CD47 drug trials from its...
Microbiome and Environmental Health Discoveries
New research reveals critical roles for microbiota and environmental factors in human and ecological health. A mouse study demonstrated that human gut bacteria can bioaccumulate “forever...
Innovations in Genetic Engineering and Genome Editing
Recent innovations in genome editing reveal transformative potential. Researchers introduced a near-infrared-activated chemically induced CRISPR system enabling precise spatiotemporal control of...
SGLT2 Inhibitors and Cancer Survival Insights
New clinical evidence expands indications for existing classes of drugs. A retrospective cohort study published in BMC Cancer suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), typically...
Market and Industry Developments in Biotech and Healthcare
The biotech sector reflects mixed trends: Sage Therapeutics plans massive layoffs following its acquisition by Supernus Pharmaceuticals amid pipeline challenges. Major venture capital disputes...
AbbVie’s $2.1B Bet on In Vivo CAR-T Platform Signals Immunotherapy Push
AbbVie has agreed to acquire Capstan Therapeutics in a deal valued up to $2.1 billion, advancing the pharma giant’s in vivo CAR-T therapy ambitions. Capstan’s technology enables direct engineering...
Moderna’s mRNA Flu Vaccine Surpasses Competitor in Large Phase 3 Trial
Moderna’s seasonal influenza vaccine candidate, mRNA-1010, demonstrated a 26.6% relative vaccine efficacy over a licensed standard-dose seasonal influenza vaccine in adults aged 50 and older...
Sage Therapeutics to Slash Workforce After Supernus Acquisition
Sage Therapeutics, soon to be acquired by Supernus Pharmaceuticals, plans to lay off approximately 338 employees, representing the vast majority of its workforce. This decision follows Supernus’s...